Proactive Investors - Run By Investors For Investors

ANGLE's parsortix gets favourable peer review for use in therapy selection

"The incorporation of Parsortix in protocols for therapy selection has the potential to meet a key need in personalised medicine.
picture of blood sample
The University Medical Centre Hamburg-Eppendorf (UKE) published new research
ANGLE PLC’s (LON:AGL OTCQX:ANPCY) cancer cell collection technology has received another encouraging peer review in a leading scientific journal.
 
The University Medical Centre Hamburg-Eppendorf (UKE) published new research detailing the use of ANGLE's Parsortix system in the Clinical Chemistry journal.
 
ANGLE's chief executive, Andrew Newland, said: "This fourth peer-reviewed publication in a key scientific journal adds to the growing body of published evidence of 
Parsortix's superior performance as a liquid biopsy.  
 
"The incorporation of Parsortix in protocols for therapy selection has the potential to meet a key need in personalised medicine. 
 
“By facilitating the determination of which drugs will benefit individual patients and which will have little clinical benefit yet cause significant side effects, such protocols will also help reduce the burden on expensive healthcare resources."
 
Klaus Pantel, chairman, Department of Tumour Biology at UKE's Centre of Experimental Medicine, added: "We are excited about the new workflows utilising Parsortix to study multi marker profiles of single CTCs by low cost qPCR approaches.  
 
“The high expression levels of chemokines achieved with Parsortix offers the potential for its use in therapy selection for patients and we will be progressing further studies to determine specific applications."
View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

1528098797_Biotech-lab.jpg
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use